Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects
Highlight
– Henagliflozin treatment significantly increased telomere length, a key biomarker of cellular aging, in patients with type 2 diabetes.
– The drug elevated insulin-like growth factor-binding protein-3 (IGFBP-3) and β-hydroxybutyrate levels, indicative of beneficial metabolic modulation.
– Enhanced cytotoxic T lymphocyte (CTL) function was evidenced by increased granzyme B expression, suggesting improved immune surveillance.
– Metabolomic profiling revealed upregulation of thiamine levels and metabolism, pointing to multiple pathways of potential anti-aging effects.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.